You Searched For: THI Total Healthcare Innovation GmbH
2,764 results were found
~~Microsoft Word - 101201_GHS-Customer Letter_vF _RHo_.docx~~
/m-ni.vwr.com/en_NI/images/GHS_Customer_Letter.pdf
Microsoft Word - 101201_GHS-Customer Letter_vF _RHo_.docx VWR International Management Services GmbH & Co. KG Hilpertstraße 20A · D-64295 Darmstadt Tel. +49 6151 3972-0 · www.vwr.com VWR International Management Services GmbH & Co. KG HypoVereinsb...
~~Microsoft Word - 101201_GHS-Customer Letter_vF _RHo_.docx~~
/m-sg.vwr.com/en_SG/images/GHS_Customer_Letter.pdf
Microsoft Word - 101201_GHS-Customer Letter_vF _RHo_.docx VWR International Management Services GmbH & Co. KG Hilpertstraße 20A · D-64295 Darmstadt Tel. +49 6151 3972-0 · www.vwr.com VWR International Management Services GmbH & Co. KG HypoVereinsb...
~~Avantor Services Success Story Biorepository Servi~~
/m-ca.vwr.com/fr_CA/images/Avantor_Services_Success_Story_Biorepository_Servi.pdf
CHALLENGE A top 25 biopharmaceutical company was using various external contract research organizations (CROs) to conduct GLP studies in order to support product development and new drug candidate submissions. After over 15 years of conducting the...
ls ge29064295 20131220222354
/m-sk.vwr.com/sk_SK/images/ls_ge29064295_20131220222354.pdf
imagination at work Application note 29-0642-95 AA Chromatography systems Depletion of albumin from serum samples using ÄKTA™ start Albumin comprises 55% to 65% of the total protein in serum. The abundance of this protein makes it difficult to stu...
~~ls ge29064295 20131220222354~~
/uk.vwr.com/en_GB/images/ls_ge29064295_20131220222354.pdf
imagination at work Application note 29-0642-95 AA Chromatography systems Depletion of albumin from serum samples using ÄKTA™ start Albumin comprises 55% to 65% of the total protein in serum. The abundance of this protein makes it difficult to stu...
ls ge29064295 20131220222354
/m-be.vwr.com/nl_BE/images/ls_ge29064295_20131220222354.pdf
imagination at work Application note 29-0642-95 AA Chromatography systems Depletion of albumin from serum samples using ÄKTA™ start Albumin comprises 55% to 65% of the total protein in serum. The abundance of this protein makes it difficult to stu...
ls ge29064295 20131220222354
/m-pl.vwr.com/pl_PL/images/ls_ge29064295_20131220222354.pdf
imagination at work Application note 29-0642-95 AA Chromatography systems Depletion of albumin from serum samples using ÄKTA™ start Albumin comprises 55% to 65% of the total protein in serum. The abundance of this protein makes it difficult to stu...
ls ge29064295 20131220222354
/m-pt.vwr.com/pt_PT/images/ls_ge29064295_20131220222354.pdf
imagination at work Application note 29-0642-95 AA Chromatography systems Depletion of albumin from serum samples using ÄKTA™ start Albumin comprises 55% to 65% of the total protein in serum. The abundance of this protein makes it difficult to stu...
ls ge29064295 20131220222354
/m-no.vwr.com/no_NO/images/ls_ge29064295_20131220222354.pdf
imagination at work Application note 29-0642-95 AA Chromatography systems Depletion of albumin from serum samples using ÄKTA™ start Albumin comprises 55% to 65% of the total protein in serum. The abundance of this protein makes it difficult to stu...
~~Avantor Services Success Story Biorepository Servi~~
/m-us.vwr.com/en_US/images/Avantor_Services_Success_Story_Biorepository_Servi.pdf
CHALLENGE A top 25 biopharmaceutical company was using various external contract research organizations (CROs) to conduct GLP studies in order to support product development and new drug candidate submissions. After over 15 years of conducting the...
~~29188433AA Production of recombinant monoclonal an~~
/m-dk.vwr.com/da_DK/images/29188433AA_Production_of_recombinant_monoclonal_an.pdf
1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...
~~29188433AA Production of recombinant monoclonal an~~
/m-nl.vwr.com/nl_NL/images/29188433AA_Production_of_recombinant_monoclonal_an.pdf
1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...
~~29188433AA Production of recombinant monoclonal an~~
/m-no.vwr.com/no_NO/images/29188433AA_Production_of_recombinant_monoclonal_an.pdf
1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...
~~29188433AA Production of recombinant monoclonal an~~
/m-pl.vwr.com/pl_PL/images/29188433AA_Production_of_recombinant_monoclonal_an.pdf
1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...
~~29188433AA Production of recombinant monoclonal an~~
/m-in.vwr.com/en_IN/images/29188433AA_Production_of_recombinant_monoclonal_an.pdf
1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...
29188433AA Production of recombinant monoclonal an
/m-ch.vwr.com/it_CH/images/29188433AA_Production_of_recombinant_monoclonal_an.pdf
1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...
1 - 16 of 2,764